文献速递MDS 与骨髓增殖性肿瘤

骨髓增殖性肿瘤分子机制生物学及治疗靶向

Biology and therapeutic targeting of molecular mechanisms in MPNs.
PubMed 文献 · Blood · 2023-01-01

骨髓增殖性肿瘤(MPN)是JAK-STAT信号激活的克隆性造血干细胞疾病,JAK抑制剂为骨髓纤维化(MF)标准治疗但未显著改变病程。本文综述疾病发病机制最新数据,并聚焦靶向JAK2突变干细胞、JAK与非JAK通路、突变钙网蛋白及炎性骨髓微环境的新兴疗法。

要点

  • JAK抑制剂改善MPN相关症状,但未显著改变MF疾病进程。
  • ET和PV治疗主要降低心血管和血栓栓塞并发症风险,低血栓风险者常观察等待。
  • 对MPN生物学的深入理解促成合理设计疗法,目标兼顾并发症与疾病修饰。

核心结论

  • 对MPN生物学的深入理解已促成合理设计的疗法,目标不仅是处理疾病并发症,还可能改变疾病进程。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • MPN为克隆性造血干细胞疾病,以JAK-STAT信号激活为特征。
  • 已获批JAK抑制剂可改善MPN相关症状,但未已知显著改变MF病程。
  • ET和PV治疗主要降低心血管和血栓栓塞并发症风险,低血栓风险者常采用观察等待。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by activated Janus kinase (JAK)-signal transducer and activator of transcription signaling. As a result, JAK inhibitors have been the standard therapy for treatment of patients with myelofibrosis (MF). Although currently approved JAK inhibitors successfully ameliorate MPN-related symptoms, they are not known to substantially alter the MF disease course. Similarly, in essential thrombocythemia and polycythemia vera, treatments are primarily aimed at reducing the risk of cardiovascular and thromboembolic complications, with a watchful waiting approach often used in patients who are considered to be at a lower risk for thrombosis. However, better understanding of MPN biology has led to the development of rationally designed therapies, with the goal of not only addressing disease complications but also potentially modifying disease course. We review the most recent data elucidating mechanisms of disease pathogenesis and highlight emerging therapies that target MPN on several biologic levels, including JAK2-mutant MPN stem cells, JAK and non-JAK signaling pathways, mutant calreticulin, and the inflammatory bone marrow microenvironment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. How J, Garcia JS, Mullally A, et al. Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. 2023. PMID: 36534936. doi:10.1182/blood.2022017416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。